Method of treating conditions of the eye with an anti-vegf darpin
OwnerThomas Hohman, Janet Cheetham +2inventors
InventorsThomas Hohman, Janet Cheetham, Scott Whitcup, Erik Lippa
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for the treatment of a patient having an exudative age-related macular degeneration and other conditions of the retina by administering a binding protein comprising an ankyrin repeat domain, wherein the binding protein is first administered in 2 to 5 doses, with an interval of 25 to 35 days between each dose, and then is administered in additional doses with a longer interval between doses.
Claims21
A method of treating exudative macular degeneration, the method comprising:
- (a) administering, to an eye of a patient in need of such treatment, 3 initial doses of about 1 mg to about 2 mg of a recombinant binding protein comprising SEQ ID NO:
- 3, with an interval of 28 days between each dose;
- and
- (b) administering to the eye at least one additional dose of the same amount of the binding protein, with an interval of 56 days between the last initial dose and the first additional dose and between any other additional doses.
A method of treating exudative macular degeneration, the method comprising (a) administering, via intravitreal injection to an eye of a patient in need of such treatment, three initial doses of about 1 mg to about 2 mg of a recombinant binding protein comprising SEQ ID NO:
- 3, with an interval of 28 days between each dose;
- (b) administering to the eye at least one additional dose of the same amount of the binding protein, with an interval of 84 days between the last initial dose and the first additional dose and between any other additional doses.
Dependencies are inferred from the claim text.